DeepMed Research

GROUPE FRANCOPHONE DES MYELODYSPLASIES

🇫🇷France

Country: 🇫🇷France

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Azacitidine combined to Lenalidomide

First Posted Date: 2010-03-17

Last Posted Date: 2017-12-15

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 50

Registration Number: NCT01088373

Locations: 🇫🇷
Hôpital la pitié-Salpétrière, Paris, France
🇫🇷
CHU Bretonneau, Tours, France
🇫🇷
Hôpital PURPAN, Service d'Hématologie Clinique, Toulouse, France

and more 31 locations

Erlotinib in Higher Risk Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Erlotinib

First Posted Date: 2010-03-12

Last Posted Date: 2016-11-08

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 30

Registration Number: NCT01085838

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CHRU Huriez, Lille, France
🇫🇷
Hôpital Avicenne, Bobigny, France

and more 11 locations

Clofarabine in High Risk Myelodysplastic Syndrome (MDS)

Phase 1

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Clofarabine

First Posted Date: 2010-02-05

Last Posted Date: 2014-03-19

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 76

Registration Number: NCT01063257

Locations: 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Hôpital Saint-Louis, Paris, France

and more 2 locations

Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Azacitidine
Drug: Epoetin beta

First Posted Date: 2009-11-18

Last Posted Date: 2014-03-19

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 98

Registration Number: NCT01015352

Locations: 🇫🇷
Hôpital Brabois, Nancy, France
🇫🇷
Hôpital Avignon, Avignon, France
🇫🇷
Hôpital Archet1, Nice, France

and more 26 locations

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Phase 2

Conditions: Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia
Acute Myeloid Leukemia

Interventions: Drug: Lenalidomide

First Posted Date: 2009-04-22

Last Posted Date: 2015-04-24

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 85

Registration Number: NCT00885508

Locations: 🇫🇷
Centre henri Mondor, Creteil, France
🇫🇷
CH Angers, Angers, France
🇫🇷
hopital Victor Dupouy, Argenteuil, France

and more 22 locations

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Phase 1

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: VORINOSTAT

First Posted Date: 2008-10-21

Last Posted Date: 2014-03-20

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 52

Registration Number: NCT00776503

Locations: 🇫🇷
CH René Dubos, Cergy-pontoise, France
🇫🇷
Hematology Dpt, Hôpital Sud Francilien, Corbeil-essonnes, France
🇫🇷
Hôpital de la Durance, Avignon, France

and more 11 locations

Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200

Phase 2

Completed

Conditions: Myelodysplastic Syndromes

First Posted Date: 2007-04-04

Last Posted Date: 2007-04-04

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 112

Registration Number: NCT00455910

Locations: 🇫🇷
CHU Albert Michallon, Grenoble, France
🇫🇷
CH d'Avignon, Avignon, France
🇫🇷
Hopital Avicenne, Bobigny, France

and more 17 locations

A Phase II Study of Maintenance With Azacitidine in MDS Patients

Phase 2

Terminated

Conditions: Leukemia, Myelocytic, Acute
Myelodysplastic Syndromes

First Posted Date: 2007-03-12

Last Posted Date: 2012-01-19

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 39

Registration Number: NCT00446303

Locations: 🇫🇷
CHU de Caen, Caen, France
🇫🇷
CHU d'Amiens, Amiens, France
🇫🇷
Hopital d'Instruction des Armées Percy, Clamart, France

and more 22 locations

Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)

Phase 2

Conditions: Myelodysplastic Syndromes

First Posted Date: 2007-03-06

Last Posted Date: 2007-05-17

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 99

Registration Number: NCT00443339

Locations: 🇫🇷
CHU d'Avignon, Avignon, France
🇫🇷
Hopital Percy, Clamart, France
🇫🇷
CHU de Caen, Caen, France

and more 24 locations

Treatment of the Anemia of Myelodysplastic Syndromes by the Association of Epoetin Beta and All Trans Retinoic Acid

Phase 2

Conditions: Anemia in Myelodysplastic Syndromes

First Posted Date: 2007-02-21

Last Posted Date: 2009-11-18

Lead Sponsor: Groupe Francophone des Myelodysplasies

Target Recruit Count: 99

Registration Number: NCT00437450

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
CHU d'Avignon, Avignon, France
🇫🇷
CHU de Caen, Caen, France

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy